ストックスクリーナーアプリを入手
0.3237
4.22%
-0.0152
前日終値:
$0.3389
開ける：
$0.3385
24時間の取引高:
592.73K
Relative Volume:
0.24
時価総額：
$2.96M
収益：
$749.50K
当期純損益:
$-29.60M
株価収益率:
-0.000861
EPS:
-376.0263
ネットキャッシュフロー:
$-22.09M
1週間 パフォーマンス:
-6.86%
1か月 パフォーマンス:
-70.22%
6か月 パフォーマンス:
-99.61%
1年 パフォーマンス:
-99.77%
1日の値動き範囲:
$0.3161
$0.3388
1週間の範囲:
$0.31
$0.3789
52週間の値動き範囲:
$0.31
$380.00
Aditxt Inc Stock (ADTX) Company Profile
ADTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ADTX | 0.3237 | 2.96M | 749.50K | -29.60M | -22.09M | -376.03 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.68 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aditxt Inc (ADTX) 最新ニュース
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartzy
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com
Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan
Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World
Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks
A Biotech Empire Rises in Inland Southern California - Site Selection Magazine
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans - Investing.com
Evofem Biosciences Faces Merger and Credit Challenges - TipRanks
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com
Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com
Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow
ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan
Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa
Aditxt Inc (ADTX) 財務データ
収益
当期純利益
現金流量
EPS
Aditxt Inc (ADTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):